CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity
Fig 5
Depletion of T cells or NK cells negatively impacts the anti-tumor efficacy of mCD38-mAtt.
Immunocompetent BALB/c mice were inoculated with A–C, A20, or D–F, CT26 cells and when tumors reached an average volume of ~ 100 mm3, mice were randomized into treatment groups and administered αAsialo GM-1- (A, D), αCD8- (B, E), or αCD4- (C, F) depleting antibodies to deplete specific immune cell subtypes, starting 1 day prior to drug treatment (day -1), and continuing weekly thereafter through the duration of the experiment. On day 0, mice were treated with a single dose of vehicle (PBS, 200 µ L final volume) or 10 mg/kg mCD38-mAtt and tumor volume was measured twice weekly until humane endpoint for vehicle control groups was reached.